2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 944

Predict the Chance of Remission for Your RA Patient in Real Life
Abstract Number: 669

Predicted Chronic Exposure and Dose Selection for Belimumab Administered Subcutaneously to SLE Patients
Abstract Number: 303

Predicting Chronic Pain in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Prospective Study
Abstract Number: 2030

Predicting Failure of Conventional Disease Modifying Antirheumatic Drugs in Treatment Naive Early Rheumatoid Arthritis Patients: A Single Centre Inception Prognostic Factor Cohort Study
Abstract Number: 1310

Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis
Abstract Number: 1775

Predicting Relapse in Patients with Granulomatosis with Polyangiitis – the Potential Use of Monitoring in Vitro ANCA Production
Abstract Number: 1920

Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins
Abstract Number: 1542

Predicting Successful Long-Term Treatment with Tumour Necrosis Factor-Alpha Inhibitors in Patients with Psoriatic Arthritis
Abstract Number: 1740

Predicting the Evolution of Inflammatory Arthritis in ACPA-Positive Individuals: Can T-Cell Subsets Model Help?
Abstract Number: 271

Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN)
Abstract Number: 728

Prediction and Impact of Attacks of Raynaud’s Phenomenon, As Judged By Patient perception
Abstract Number: 730

Prediction of Cardiac and Vascular Events in Systemic Sclerosis: Input from Endothelin-1 Type a Receptor Antibodies
Abstract Number: 722

Prediction of Improvement in Skin Fibrosis in Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 1081

Prediction of Mortality Risk Related to Cerebrovascular Accidents in Patients with Systemic Lupus Erythematosus (SLE) vs Anti-Phospho-Lipid-Antibody (aPL) syndrome
Abstract Number: 2493

Prediction of Remission and Low Disease Activity in DMARD-Refractory Patients with RA Treated with Golimumab

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].